Cite
Ferreira AR, Bettencourt M, Alho I, et al. Serum YB-1 (Y-box binding protein 1) as a biomarker of bone disease progression in patients with breast cancer and bone metastases. J Bone Oncol. 2017;6:16-21doi: 10.1016/j.jbo.2017.01.002.
Ferreira, A. R., Bettencourt, M., Alho, I., Costa, A. L., Sousa, A. R., Mansinho, A., Abreu, C., Pulido, C., Macedo, D., Vendrell, I., Pacheco, T. R., Costa, L., & Casimiro, S. (2017). Serum YB-1 (Y-box binding protein 1) as a biomarker of bone disease progression in patients with breast cancer and bone metastases. Journal of bone oncology, 616-21. https://doi.org/10.1016/j.jbo.2017.01.002
Ferreira, A R, et al. "Serum YB-1 (Y-box binding protein 1) as a biomarker of bone disease progression in patients with breast cancer and bone metastases." Journal of bone oncology vol. 6 (2017): 16-21. doi: https://doi.org/10.1016/j.jbo.2017.01.002
Ferreira AR, Bettencourt M, Alho I, Costa AL, Sousa AR, Mansinho A, Abreu C, Pulido C, Macedo D, Vendrell I, Pacheco TR, Costa L, Casimiro S. Serum YB-1 (Y-box binding protein 1) as a biomarker of bone disease progression in patients with breast cancer and bone metastases. J Bone Oncol. 2017 Jan 28;6:16-21. doi: 10.1016/j.jbo.2017.01.002. eCollection 2017 Mar. PMID: 28194325; PMCID: PMC5294742.
Copy
Download .nbib